The Graves Diseases drugs in development market research report provides comprehensive information on the therapeutics under development for Graves Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Graves Diseases. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Graves Diseases and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Graves Diseases by 16 companies/universities/institutes. The top development phase for Graves Diseases is preclinical with eight drugs in that stage. The Graves Diseases pipeline has 16 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Graves Diseases pipeline products market are: HanAll Biopharma, Crinetics Pharmaceuticals and advanceCor.
The key targets in the Graves Diseases pipeline products market include Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR), IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN), and Interleukin 6 (B Cell Stimulatory Factor 2 or BSF2 or CTL Differentiation Factor or CDF or Hybridoma Growth Factor or Interferon Beta 2 or IFNB2 or IL6).
The key mechanisms of action in the Graves Diseases pipeline product include Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR) Antagonist with four drugs in Phase I. The Graves Diseases pipeline products include five routes of administration with the top ROA being Subcutaneous and five key molecule types in the Graves Diseases pipeline products market including Monoclonal Antibody, and Small Molecule.
Graves Diseases overview
Graves’ disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes, and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking, and pregnancy. Treatment includes anti-thyroid medications, beta blockers, and surgery.
For a complete picture of Graves Diseases’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
